<unk>  (INN; trade name Takhzyro) is a human monoclonal antibody (class IgG1 kappa) that targets plasma kallikrein (pKal) in order to promote prevention of angioedema in patients with hereditary angioedema.<unk> , was approved in the United States as the first monoclonal antibody indicated for prophylactic treatment to prevent hereditary angioedema (HAE) attacks. Takhzyro is the first treatment for hereditary angioedema (HEA) prevention made by using cells within a lab, not human plasma. The US Food and Drug Administration approved the use of<unk>  on 23 August 2018 for patients that are 12 years and older and suffering from either type I or type II hereditary angioedema (HEA). Administration of the medication is done through 1 subcutaneous injection at a dose of 300 milligrams every 2 weeks (every 4-week dosing can be considered in specific patients). In phase 1 clinical trials<unk>  was well tolerated and was reported to reduce cleavage of kininogen in the plasma of patients with hereditary angioedema and decrease the number of patients experiencing attacks of angioedema.<unk> ’s approval in the United States was spearheaded by the data presented in the phase 1b, multicenter, double blind, placebo controlled, multi-ascending-dose trial. Through this trial,<unk>  was given Priority Review, Breakthrough Therapy, Orphan Drug designation by the FDA. The phase 3 HELP study evaluated efficacy and safety of<unk> . This drug was produced by Dyax Corp and currently under development by Shire. Common side effects include pain associated with injection site reactions, injection site bruising, upper respiratory infection, headache, rash, myalgia, dizziness, and diarrhea.
Lanadelumab
Ustekinumab
Olaratumab
Alirocumab
Evolocumab
Tralokinumab
Evinacumab
Emapalumab